Solorank.ai
Login

Cached score snapshot

US.DGX · Quest Diagnostics

110分制 50.8/110；5D動能v2 5/50；排序分 55.8/160

Back to ranking Open volume snapshot
Ranking score 55.8/160
Main score 50.8/110
5D momentum v2 5/50
Rank #280
Setup grade F 24

Score breakdown

避免

Medium twelvedata

Score and price trend

F 24 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-12 07-28 09-09 09-30 10-20 $185.87$236.33$286.80 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.226 · anchors 120 +1.71% -0.28% / +3.89% 70% 1.3% Actual -0.20% · vs median -1.91% · inside 25-75 band
30D observation +7.59% +0.83% / +13.68% 77.5% 6.3% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +1.73% -0.21% / +4.61% 70% 1.3% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-12 → 2026-10-20 · 119 archived points · 2 Improving turn signal · 5 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 55.8
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 50.8/110 (避免)
5D momentum v2 5/50 (弱)
Score with momentum v2 55.8/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 239.752
ma50 228.05
close 235.5
prevClose 237.14
avgVolume20 848905
volumeRatio 0.85
changePercent -0.69

Metrics snapshot

close 235.5
volume 724003
changePercent -0.69

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 50.8/110
Main rating 避免
5D momentum v2 5/50
Score with momentum v2 55.8/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 3.7/5 · 良好
Dimension score 3.7/5
Dimension grade 良好

Sub-items

pbPoints 0.4
pePoints 0.4
epsPoints 0.4
roePoints 0.4
debtPoints 0.4
marginPoints 0
turnoverUsdM 170.5027
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 6.8/20 · 較差
Dimension score 6.8/20
Dimension grade 較差

Sub-items

cmfPoints 1.6
mfiPoints 1.6
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.DGX
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 9.6/15 · 一般
Dimension score 9.6/15
Dimension grade 一般

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 15.3

trend

score 3.4

details

qqq

ma20 717.385
ma50 711.3218
name QQQ
close 718.36
points 2

spy

ma20 768.6995
ma50 757.5966
name SPY
close 765.96
points 1.4
source twelvedata+fred
atrPct 2.1575
atrPoints 3
cciPoints 0.8
vixPoints 2.4
marketTrendPoints 3.4

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 0
catalystPoints 2

風險管理 — 7.2/10 · 良好
Dimension score 7.2/10
Dimension grade 良好

Sub-items

position

score 1.4

details

atrPct 2.1575
turnoverUsdM 170.5027
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DGX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 225.3384

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 4.3
take_profit_price 247.275
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.3149
diversificationPoints 2

技術信號 — 17.5/30 · 較差
Dimension score 17.5/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 2.2
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 2.2
vcp_reason 波幅收縮(9.4%→5%)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N

vcp_metrics

up_days 3
vol_ref 876123.3333
down_days 6
vcp_ready true
above_ma50 true
avg_vol_10 899520
avg_vol_20 855510
avg_vol_30 876123.3333
range_pct_10 0.0501
range_pct_20 0.0633
range_pct_30 0.0944
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 1.0267
dist_to_20d_high 0.0473
down_shrink_days 4
breakout_level_20d 247.19
vcp_breakout_confirm false
contraction_ratio_10_30 0.5315
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 3
sentimentScoreRaw 0.9

sentimentData

raw {"id":141408008,"url":"https://finnhub.io/api/news?id=7e265a133c957b1e633a2178b581bff46b7f58d4be1a68ea313b16f299e10419","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...","category":"company","datetime":1788498563,"headline":"Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX"}, {"id":141283760,"url":"https://finnhub.io/api/news?id=c30d5354e46ad88c54ed8c721c8bdc3fcb2949ea541ef2057d4c3ec993cc5c35","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.","category":"company","datetime":1787330580,"headline":"Is it the Right Time to Retain DGX Stock in Your Portfolio?"}, {"id":141283764,"url":"https://finnhub.io/api/news?id=b4fc9be2a5861ea980b8fcafad24bd1e28e83c7234cd7a90abacddcf2d4626b4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.","category":"company","datetime":1787321702,"headline":"Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?"}, {"id":141283761,"url":"https://finnhub.io/api/news?id=9b7af376234d46216302cd1b88a42b88d804fa085ac0af9da002e6be19e4f53e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...","category":"company","datetime":1787209981,"headline":"Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal"}, {"id":141283766,"url":"https://finnhub.io/api/news?id=153a33d2b30a5f92b854b9cf7cbc805d6166ef3aa40451807b72088301a25ba7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...","category":"company","datetime":1787188641,"headline":"Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?"}, {"id":141283762,"url":"https://finnhub.io/api/news?id=dbf64f79f64fd58736b6a3e1dbf8ec71613e7a372c25d65fe8dc17f2fed7e0c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.","category":"company","datetime":1787072404,"headline":"Quest Diagnostics (DGX) Upgraded to Buy: Here's Why"}, {"id":141244640,"url":"https://finnhub.io/api/news?id=20953e31f24da77a3f33a10b4c7fbcd3a7381e5351819e80edfc211f24131541","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"DGX","summary":"Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.","category":"company","datetime":1787041268,"headline":"Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield"}, {"id":141283763,"url":"https://finnhub.io/api/news?id=3799321850299dfebd18e307c44194a4182bd06002047280bc17baaf4916e732","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.","category":"company","datetime":1786726802,"headline":"Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know"}
raw_source {"id":141951221,"url":"https://finnhub.io/api/news?id=5f0ccb5ba37ed2618b1c737f27fa3e8f9f760cf7074a72a068ccba82d24d4b12","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.","category":"company","datetime":1788873661,"headline":"Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million"}, {"id":141481712,"url":"https://finnhub.io/api/news?id=32dc6369c8c4692854a03ad7a10e5e7b739bfc7119a1fc5618cdb3c137eb677e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]","category":"company","datetime":1788568671,"headline":"Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?"}, {"id":141438225,"url":"https://finnhub.io/api/news?id=2bf55cc0ae8c14624d700fbe2bf2c06157061782e7f4dc6e23aa264b1b3689a5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"The global clinical laboratory services market was valued at USD 274.6 billion in 2025 and is forecast to reach USD 468.2 billion by 2036, rising from USD 298.4 billion in 2026 at a 4.6% CAGR. Growth is driven by chronic diseases, preventive healthcare, molecular diagnostics, genomic testing, precision medicine, laboratory automation, AI-enabled diagnostics, and at-home testing. North America leads, while Asia-Pacific is set for the fastest growth. The report analyzes key segments, regions, oppo","category":"company","datetime":1788532680,"headline":"Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)"}, {"id":141408008,"url":"https://finnhub.io/api/news?id=7e265a133c957b1e633a2178b581bff46b7f58d4be1a68ea313b16f299e10419","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...","category":"company","datetime":1788498563,"headline":"Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX"}, {"id":141400633,"url":"https://finnhub.io/api/news?id=595b73bf89e80d13752af49c883469a8239d7018da51accdfc2ed2fe3801f203","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788449411,"headline":"Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?"}, {"id":141362285,"url":"https://finnhub.io/api/news?id=7cc64918f3b60782ab2fbcbefa34e6aa0b5f06d064dc3153c595d7e299f4f42e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.","category":"company","datetime":1788208182,"headline":"Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest"}, {"id":141364859,"url":"https://finnhub.io/api/news?id=554fafbba1e14ea95cd6243be5acc1ef68c0f28c86ba0e0836dd5ca00d495bd0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1787848209,"headline":"Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?"}, {"id":141364854,"url":"https://finnhub.io/api/news?id=037fe18ed3f744fbda118c0af0b27be0eb5b93c5282ce3f4e4983b461daffb5e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.","category":"company","datetime":1787676763,"headline":"Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?"}, {"id":141364855,"url":"https://finnhub.io/api/news?id=40c0e04f8df859f21f445674ed5a0fe8c8ab53f395130044a40930e74d38f1f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time.","category":"company","datetime":1787668200,"headline":"Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference"}, {"id":141364860,"url":"https://finnhub.io/api/news?id=366930cf2c5ae897b40ecb560f438bf00977494bb0b55293a9e41ac2a4f2c93c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Humanity Health Inc. (\"Humanity\"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform.","category":"company","datetime":1787662800,"headline":"Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com"}, {"id":141364861,"url":"https://finnhub.io/api/news?id=e4dc0b1b814d40c40cf79420ad80a01a77b2c66b933c6d48f7296cfea76ccc2e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Digi Power X Inc (NASDAQ:DGXX, FRA:1NQ0, NEO:DGX) insiders bought shares in back-to-back open-market purchases this week, according to regulatory filings. President and director Amar Alec purchased 10,000 subordinate voting shares on August 20 at a weighted average price of $3.86 per share,...","category":"company","datetime":1787589540,"headline":"Digi Power X president, CEO both buy shares in open-market purchases"}, {"id":141364857,"url":"https://finnhub.io/api/news?id=964fad4e5c5ddf7fc03e7aa4be78e049a882b812bb77d8a66a6c9b4dfb3aa097","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Roche (USOTC:RHHBY) and Eli Lilly (NYSE:LLY) have secured clearance from the U. S.","category":"company","datetime":1787580020,"headline":"Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test"}, {"id":141364862,"url":"https://finnhub.io/api/news?id=759779a4821281c00895f8de60489581308fa566201fbf8469ce39e9382d6030","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m. Eastern Time.","category":"company","datetime":1787580000,"headline":"Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference"}, {"id":141313595,"url":"https://finnhub.io/api/news?id=ab28c9e7a274e4f583b5fe92bfea124c02a7193f9a8cd91780241995a932a554","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"AMGN, FCFS and DK delivered strong gains, highlighting Zacks research successes across several model portfolios.","category":"company","datetime":1787577660,"headline":"Beat the Market Like Zacks: Amgen, FirstCash, Delek in Focus"}, {"id":141364856,"url":"https://finnhub.io/api/news?id=2b1574465aa601226261d6435757263297ba3a8d7e5054789679f8494b04b917","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.","category":"company","datetime":1787574240,"headline":"Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology"}, {"id":141309939,"url":"https://finnhub.io/api/news?id=ebc0b9f8f80338232508ef310cd9f7e513d35103dae6bae94768eaa13974e583","image":"","source":"Benzinga","related":"DGX","summary":"Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10%","category":"company","datetime":1787556470,"headline":"Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation"}, {"id":141283760,"url":"https://finnhub.io/api/news?id=c30d5354e46ad88c54ed8c721c8bdc3fcb2949ea541ef2057d4c3ec993cc5c35","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.","category":"company","datetime":1787330580,"headline":"Is it the Right Time to Retain DGX Stock in Your Portfolio?"}, {"id":141283764,"url":"https://finnhub.io/api/news?id=b4fc9be2a5861ea980b8fcafad24bd1e28e83c7234cd7a90abacddcf2d4626b4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.","category":"company","datetime":1787321702,"headline":"Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?"}, {"id":141275203,"url":"https://finnhub.io/api/news?id=089773ba910b7d77165aa048f75b768edf24f1414da740123cd9e15d62e665de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.","category":"company","datetime":1787257290,"headline":"Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash"}, {"id":141283761,"url":"https://finnhub.io/api/news?id=9b7af376234d46216302cd1b88a42b88d804fa085ac0af9da002e6be19e4f53e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...","category":"company","datetime":1787209981,"headline":"Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal"}, {"id":141283766,"url":"https://finnhub.io/api/news?id=153a33d2b30a5f92b854b9cf7cbc805d6166ef3aa40451807b72088301a25ba7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...","category":"company","datetime":1787188641,"headline":"Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?"}, {"id":141283762,"url":"https://finnhub.io/api/news?id=dbf64f79f64fd58736b6a3e1dbf8ec71613e7a372c25d65fe8dc17f2fed7e0c9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.","category":"company","datetime":1787072404,"headline":"Quest Diagnostics (DGX) Upgraded to Buy: Here's Why"}, {"id":141283776,"url":"https://finnhub.io/api/news?id=04b264d86ac1e07f5d8e919b4a93debd01928f472f7c923b1748772de3656742","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"BOSTON, August 18, 2026--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX).","category":"company","datetime":1787061600,"headline":"WHOOP Makes Advanced Labs Available Without a Wearable Membership"}, {"id":141244640,"url":"https://finnhub.io/api/news?id=20953e31f24da77a3f33a10b4c7fbcd3a7381e5351819e80edfc211f24131541","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"DGX","summary":"Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.","category":"company","datetime":1787041268,"headline":"Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield"}, {"id":141231125,"url":"https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"DGX","summary":"Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.","category":"company","datetime":1786867596,"headline":"IHF: Healthcare Dashboard For August"}, {"id":141283763,"url":"https://finnhub.io/api/news?id=3799321850299dfebd18e307c44194a4182bd06002047280bc17baaf4916e732","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.","category":"company","datetime":1786726802,"headline":"Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know"}, {"id":141233184,"url":"https://finnhub.io/api/news?id=b2a121b5b85a7a5508e3d6aaa99f21902c8482bf25c1589fc2188a9960960350","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.","category":"company","datetime":1786725000,"headline":"HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up"}, {"id":141206759,"url":"https://finnhub.io/api/news?id=c067faf0c1634ac60f102352c75ddfeda8c69f0af93964e9e913b74018d3c1e7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.","category":"company","datetime":1786626180,"headline":"National Vision Stock Down Despite Q2 Earnings & Revenue Beat"}, {"id":141206752,"url":"https://finnhub.io/api/news?id=659ee02b225f8ed4a921b6c898a8d79914a526a79eab67069f99e681ffb2582e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.","category":"company","datetime":1786626060,"headline":"TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises"}, {"id":141202450,"url":"https://finnhub.io/api/news?id=18bb8e50654636d5475babe63b4fb5fb1d1b65d919e63f3813f91c80c4740dbe","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.","category":"company","datetime":1786565700,"headline":"Quest Diagnostics Declares Quarterly Cash Dividend"}, {"id":141199695,"url":"https://finnhub.io/api/news?id=83b406a895b2ed6e006d593db9ba4a3e8ee2ebbb0837d4baec2ecbb05543e816","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.","category":"company","datetime":1786468740,"headline":"Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down"}, {"id":141202446,"url":"https://finnhub.io/api/news?id=bab940f55a7015d88f60068e2a5c3a85f4cdee542e259b301b823c86d91a00e2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.","category":"company","datetime":1786454220,"headline":"Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs"}, {"id":141175551,"url":"https://finnhub.io/api/news?id=335ee49202be9ffff32971915dd2c0726283f0b283c39a280888d2ccb6cbefef","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.","category":"company","datetime":1786373040,"headline":"Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?"}, {"id":141175552,"url":"https://finnhub.io/api/news?id=eee9f1f73ba5090380f2701c2893296c2b81648f037f5e89f4a44803cadf2233","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"DGX","summary":"Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.","category":"company","datetime":1786368120,"headline":"PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 3
recomputed_at_score true
sentiment_score_raw 0.9
source_article_count 34
discarded_article_count 26
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 3.7 5/110 74% 3.7
資金流 6.8 20/110 34% 6.8
市場環境 9.6 15/110 64% 9.6
催化劑 2 20/110 10% 2
風險管理 7.2 10/110 72% 7.2
技術信號 17.5 30/110 58.33% 17.5
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 5/50
ret_5d -0.02
max_score 50
max_total 50
raw_total 5
vcp_bonus 0
vol_ratio 0.8463
ret_points 0
vol_points 0
range_ratio 1.3161
volat_points 2
day_range_pct 0.0256
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 3
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.1575
turnoverUsdM 170.5027
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.DGX
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 225.3384

strength_details

ma_score 1.5
atr_score 2
rsi_score 1
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.2
stop_loss_percent 4.3
take_profit_price 247.275
target_multiplier 1.6
technical_strength 1.38
take_profit_percent 5
positionPoints 1.4
stopLossPoints 2.4

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 4.3149
diversificationPoints 2

Calculation audit log

基本面分析總分: 3.7/5分
資金流分析總分: 6.8/20分
市場環境分析總分: 9.6/15分
催化劑分析: 2/20分
風險管理總分: 7.2/10分
技術信號分析總分: 17.5/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 78.57
atr
atr 5.0808
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.16
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -112.43
cmf
rule Cursor_18.24 CMF bands
level 平衡
score 4
value 0.0038
kdj
d 39.23
j 9.59
k 29.35
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 47.1
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value -6049603
recentSlope -426210.3
previousSlope 182300
rsi
value 48.72
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 246.065
position SAR喺價上
distancePct 4.49
previousTrend 下降
ma50
value 228.05
macd
macd 2.6112
trend 中性偏多
signal 4.2361
histogram -1.6249
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 240.0979
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.85
score 4
avgVolume 848905
currentVolume 724003
derived
ma20 239.752
ma50 228.05
prevClose 237.14
avgVolume10 888150
avgVolume20 848905
changePercent -0.69
avgVolumeForScore 848905
ma_cross
ma20 239.752
ma50 228.05
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 239.8585
prevMa50 227.5376
spreadPct 5.13
isVolumeBreakout false
bollinger
lower 232.7061
upper 246.7979
position 中間
rsi_short
value 27.89
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.85

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.157452229299363,
        "turnoverUsdM": 170.5027065,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DGX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 225.3384,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.2,
      "stop_loss_percent": 4.3,
      "take_profit_price": 247.275,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.314904458598726,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 239.752,
    "ma50": 228.05,
    "close": 235.5,
    "prevClose": 237.14,
    "avgVolume20": 848905,
    "volumeRatio": 0.85,
    "changePercent": -0.69
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": -0.019975031210986316,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 0.8462823345139157,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.3160977904223312,
      "volat_points": 2,
      "day_range_pct": 0.025609299363057336,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 74,
        "contribution": 3.7
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 9.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 64,
        "contribution": 9.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 17.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58.33,
        "contribution": 17.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 50.8,
    "details": [
      "基本面分析總分: 3.7/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 9.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 17.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.7,
      "資金流": 6.8,
      "市場環境": 9.6,
      "情緒分析": 4,
      "技術信號": 17.5,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.4,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 170.5027065,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DGX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.3
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 717.3850005500001,
                "ma50": 711.3217994399997,
                "name": "QQQ",
                "close": 718.35999,
                "points": 2
              },
              "spy": {
                "ma20": 768.6994929500001,
                "ma50": 757.5966012200001,
                "name": "SPY",
                "close": 765.96002,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.157452229299363,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141408008,
                "url": "https://finnhub.io/api/news?id=7e265a133c957b1e633a2178b581bff46b7f58d4be1a68ea313b16f299e10419",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...",
                "category": "company",
                "datetime": 1788498563,
                "headline": "Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX"
              },
              {
                "id": 141283760,
                "url": "https://finnhub.io/api/news?id=c30d5354e46ad88c54ed8c721c8bdc3fcb2949ea541ef2057d4c3ec993cc5c35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Is it the Right Time to Retain DGX Stock in Your Portfolio?"
              },
              {
                "id": 141283764,
                "url": "https://finnhub.io/api/news?id=b4fc9be2a5861ea980b8fcafad24bd1e28e83c7234cd7a90abacddcf2d4626b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1787321702,
                "headline": "Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?"
              },
              {
                "id": 141283761,
                "url": "https://finnhub.io/api/news?id=9b7af376234d46216302cd1b88a42b88d804fa085ac0af9da002e6be19e4f53e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...",
                "category": "company",
                "datetime": 1787209981,
                "headline": "Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal"
              },
              {
                "id": 141283766,
                "url": "https://finnhub.io/api/news?id=153a33d2b30a5f92b854b9cf7cbc805d6166ef3aa40451807b72088301a25ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...",
                "category": "company",
                "datetime": 1787188641,
                "headline": "Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?"
              },
              {
                "id": 141283762,
                "url": "https://finnhub.io/api/news?id=dbf64f79f64fd58736b6a3e1dbf8ec71613e7a372c25d65fe8dc17f2fed7e0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
                "category": "company",
                "datetime": 1787072404,
                "headline": "Quest Diagnostics (DGX) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141244640,
                "url": "https://finnhub.io/api/news?id=20953e31f24da77a3f33a10b4c7fbcd3a7381e5351819e80edfc211f24131541",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.",
                "category": "company",
                "datetime": 1787041268,
                "headline": "Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield"
              },
              {
                "id": 141283763,
                "url": "https://finnhub.io/api/news?id=3799321850299dfebd18e307c44194a4182bd06002047280bc17baaf4916e732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1786726802,
                "headline": "Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know"
              }
            ],
            "raw_source": [
              {
                "id": 141951221,
                "url": "https://finnhub.io/api/news?id=5f0ccb5ba37ed2618b1c737f27fa3e8f9f760cf7074a72a068ccba82d24d4b12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.",
                "category": "company",
                "datetime": 1788873661,
                "headline": "Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million"
              },
              {
                "id": 141481712,
                "url": "https://finnhub.io/api/news?id=32dc6369c8c4692854a03ad7a10e5e7b739bfc7119a1fc5618cdb3c137eb677e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]",
                "category": "company",
                "datetime": 1788568671,
                "headline": "Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible?"
              },
              {
                "id": 141438225,
                "url": "https://finnhub.io/api/news?id=2bf55cc0ae8c14624d700fbe2bf2c06157061782e7f4dc6e23aa264b1b3689a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "The global clinical laboratory services market was valued at USD 274.6 billion in 2025 and is forecast to reach USD 468.2 billion by 2036, rising from USD 298.4 billion in 2026 at a 4.6% CAGR. Growth is driven by chronic diseases, preventive healthcare, molecular diagnostics, genomic testing, precision medicine, laboratory automation, AI-enabled diagnostics, and at-home testing. North America leads, while Asia-Pacific is set for the fastest growth. The report analyzes key segments, regions, oppo",
                "category": "company",
                "datetime": 1788532680,
                "headline": "Clinical Laboratory Services Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)"
              },
              {
                "id": 141408008,
                "url": "https://finnhub.io/api/news?id=7e265a133c957b1e633a2178b581bff46b7f58d4be1a68ea313b16f299e10419",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...",
                "category": "company",
                "datetime": 1788498563,
                "headline": "Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX"
              },
              {
                "id": 141400633,
                "url": "https://finnhub.io/api/news?id=595b73bf89e80d13752af49c883469a8239d7018da51accdfc2ed2fe3801f203",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449411,
                "headline": "Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?"
              },
              {
                "id": 141362285,
                "url": "https://finnhub.io/api/news?id=7cc64918f3b60782ab2fbcbefa34e6aa0b5f06d064dc3153c595d7e299f4f42e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.",
                "category": "company",
                "datetime": 1788208182,
                "headline": "Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest"
              },
              {
                "id": 141364859,
                "url": "https://finnhub.io/api/news?id=554fafbba1e14ea95cd6243be5acc1ef68c0f28c86ba0e0836dd5ca00d495bd0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1787848209,
                "headline": "Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141364854,
                "url": "https://finnhub.io/api/news?id=037fe18ed3f744fbda118c0af0b27be0eb5b93c5282ce3f4e4983b461daffb5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.",
                "category": "company",
                "datetime": 1787676763,
                "headline": "Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?"
              },
              {
                "id": 141364855,
                "url": "https://finnhub.io/api/news?id=40c0e04f8df859f21f445674ed5a0fe8c8ab53f395130044a40930e74d38f1f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time.",
                "category": "company",
                "datetime": 1787668200,
                "headline": "Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference"
              },
              {
                "id": 141364860,
                "url": "https://finnhub.io/api/news?id=366930cf2c5ae897b40ecb560f438bf00977494bb0b55293a9e41ac2a4f2c93c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Humanity Health Inc. (\"Humanity\"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform.",
                "category": "company",
                "datetime": 1787662800,
                "headline": "Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com"
              },
              {
                "id": 141364861,
                "url": "https://finnhub.io/api/news?id=e4dc0b1b814d40c40cf79420ad80a01a77b2c66b933c6d48f7296cfea76ccc2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Digi Power X Inc (NASDAQ:DGXX, FRA:1NQ0, NEO:DGX) insiders bought shares in back-to-back open-market purchases this week, according to regulatory filings. President and director Amar Alec purchased 10,000 subordinate voting shares on August 20 at a weighted average price of $3.86 per share,...",
                "category": "company",
                "datetime": 1787589540,
                "headline": "Digi Power X president, CEO both buy shares in open-market purchases"
              },
              {
                "id": 141364857,
                "url": "https://finnhub.io/api/news?id=964fad4e5c5ddf7fc03e7aa4be78e049a882b812bb77d8a66a6c9b4dfb3aa097",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Roche (USOTC:RHHBY) and Eli Lilly (NYSE:LLY) have secured clearance from the U. S.",
                "category": "company",
                "datetime": 1787580020,
                "headline": "Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test"
              },
              {
                "id": 141364862,
                "url": "https://finnhub.io/api/news?id=759779a4821281c00895f8de60489581308fa566201fbf8469ce39e9382d6030",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m. Eastern Time.",
                "category": "company",
                "datetime": 1787580000,
                "headline": "Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141313595,
                "url": "https://finnhub.io/api/news?id=ab28c9e7a274e4f583b5fe92bfea124c02a7193f9a8cd91780241995a932a554",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "AMGN, FCFS and DK delivered strong gains, highlighting Zacks research successes across several model portfolios.",
                "category": "company",
                "datetime": 1787577660,
                "headline": "Beat the Market Like Zacks: Amgen, FirstCash, Delek in Focus"
              },
              {
                "id": 141364856,
                "url": "https://finnhub.io/api/news?id=2b1574465aa601226261d6435757263297ba3a8d7e5054789679f8494b04b917",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.",
                "category": "company",
                "datetime": 1787574240,
                "headline": "Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology"
              },
              {
                "id": 141309939,
                "url": "https://finnhub.io/api/news?id=ebc0b9f8f80338232508ef310cd9f7e513d35103dae6bae94768eaa13974e583",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Test to join the company&#39;s expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10%",
                "category": "company",
                "datetime": 1787556470,
                "headline": "Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation"
              },
              {
                "id": 141283760,
                "url": "https://finnhub.io/api/news?id=c30d5354e46ad88c54ed8c721c8bdc3fcb2949ea541ef2057d4c3ec993cc5c35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Is it the Right Time to Retain DGX Stock in Your Portfolio?"
              },
              {
                "id": 141283764,
                "url": "https://finnhub.io/api/news?id=b4fc9be2a5861ea980b8fcafad24bd1e28e83c7234cd7a90abacddcf2d4626b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1787321702,
                "headline": "Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?"
              },
              {
                "id": 141275203,
                "url": "https://finnhub.io/api/news?id=089773ba910b7d77165aa048f75b768edf24f1414da740123cd9e15d62e665de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.",
                "category": "company",
                "datetime": 1787257290,
                "headline": "Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash"
              },
              {
                "id": 141283761,
                "url": "https://finnhub.io/api/news?id=9b7af376234d46216302cd1b88a42b88d804fa085ac0af9da002e6be19e4f53e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...",
                "category": "company",
                "datetime": 1787209981,
                "headline": "Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal"
              },
              {
                "id": 141283766,
                "url": "https://finnhub.io/api/news?id=153a33d2b30a5f92b854b9cf7cbc805d6166ef3aa40451807b72088301a25ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...",
                "category": "company",
                "datetime": 1787188641,
                "headline": "Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?"
              },
              {
                "id": 141283762,
                "url": "https://finnhub.io/api/news?id=dbf64f79f64fd58736b6a3e1dbf8ec71613e7a372c25d65fe8dc17f2fed7e0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
                "category": "company",
                "datetime": 1787072404,
                "headline": "Quest Diagnostics (DGX) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141283776,
                "url": "https://finnhub.io/api/news?id=04b264d86ac1e07f5d8e919b4a93debd01928f472f7c923b1748772de3656742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "BOSTON, August 18, 2026--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX).",
                "category": "company",
                "datetime": 1787061600,
                "headline": "WHOOP Makes Advanced Labs Available Without a Wearable Membership"
              },
              {
                "id": 141244640,
                "url": "https://finnhub.io/api/news?id=20953e31f24da77a3f33a10b4c7fbcd3a7381e5351819e80edfc211f24131541",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.",
                "category": "company",
                "datetime": 1787041268,
                "headline": "Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield"
              },
              {
                "id": 141231125,
                "url": "https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.",
                "category": "company",
                "datetime": 1786867596,
                "headline": "IHF: Healthcare Dashboard For August"
              },
              {
                "id": 141283763,
                "url": "https://finnhub.io/api/news?id=3799321850299dfebd18e307c44194a4182bd06002047280bc17baaf4916e732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1786726802,
                "headline": "Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know"
              },
              {
                "id": 141233184,
                "url": "https://finnhub.io/api/news?id=b2a121b5b85a7a5508e3d6aaa99f21902c8482bf25c1589fc2188a9960960350",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.",
                "category": "company",
                "datetime": 1786725000,
                "headline": "HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up"
              },
              {
                "id": 141206759,
                "url": "https://finnhub.io/api/news?id=c067faf0c1634ac60f102352c75ddfeda8c69f0af93964e9e913b74018d3c1e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.",
                "category": "company",
                "datetime": 1786626180,
                "headline": "National Vision Stock Down Despite Q2 Earnings & Revenue Beat"
              },
              {
                "id": 141206752,
                "url": "https://finnhub.io/api/news?id=659ee02b225f8ed4a921b6c898a8d79914a526a79eab67069f99e681ffb2582e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.",
                "category": "company",
                "datetime": 1786626060,
                "headline": "TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises"
              },
              {
                "id": 141202450,
                "url": "https://finnhub.io/api/news?id=18bb8e50654636d5475babe63b4fb5fb1d1b65d919e63f3813f91c80c4740dbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.",
                "category": "company",
                "datetime": 1786565700,
                "headline": "Quest Diagnostics Declares Quarterly Cash Dividend"
              },
              {
                "id": 141199695,
                "url": "https://finnhub.io/api/news?id=83b406a895b2ed6e006d593db9ba4a3e8ee2ebbb0837d4baec2ecbb05543e816",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.",
                "category": "company",
                "datetime": 1786468740,
                "headline": "Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down"
              },
              {
                "id": 141202446,
                "url": "https://finnhub.io/api/news?id=bab940f55a7015d88f60068e2a5c3a85f4cdee542e259b301b823c86d91a00e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.",
                "category": "company",
                "datetime": 1786454220,
                "headline": "Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs"
              },
              {
                "id": 141175551,
                "url": "https://finnhub.io/api/news?id=335ee49202be9ffff32971915dd2c0726283f0b283c39a280888d2ccb6cbefef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.",
                "category": "company",
                "datetime": 1786373040,
                "headline": "Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141175552,
                "url": "https://finnhub.io/api/news?id=eee9f1f73ba5090380f2701c2893296c2b81648f037f5e89f4a44803cadf2233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.",
                "category": "company",
                "datetime": 1786368120,
                "headline": "PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 34,
            "discarded_article_count": 26
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(9.4%→5%)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 876123.3333333334,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 899520,
              "avg_vol_20": 855510,
              "avg_vol_30": 876123.3333333334,
              "range_pct_10": 0.050148619957537166,
              "range_pct_20": 0.063312101910828,
              "range_pct_30": 0.0943524416135881,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0267047637889641,
              "dist_to_20d_high": 0.0472915571018245,
              "down_shrink_days": 4,
              "breakout_level_20d": 247.19,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5315031503150316
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.157452229299363,
              "turnoverUsdM": 170.5027065,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DGX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 225.3384,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.2,
            "stop_loss_percent": 4.3,
            "take_profit_price": 247.275,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.314904458598726,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 5.0808,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.16
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -112.43
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0038
    },
    "kdj": {
      "d": 39.23,
      "j": 9.59,
      "k": 29.35,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 47.1
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -6049603,
      "recentSlope": -426210.3,
      "previousSlope": 182300
    },
    "rsi": 48.72,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 246.065,
      "position": "SAR喺價上",
      "distancePct": 4.49,
      "previousTrend": "下降"
    },
    "ma50": 228.05,
    "macd": {
      "macd": 2.6112127377990078,
      "trend": "中性偏多",
      "signal": 4.236115550929118,
      "histogram": -1.6249028131301104
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 240.0979,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.85,
      "score": 4,
      "avgVolume": 848905,
      "currentVolume": 724003
    },
    "derived": {
      "ma20": 239.752,
      "ma50": 228.05,
      "prevClose": 237.14,
      "avgVolume10": 888150,
      "avgVolume20": 848905,
      "changePercent": -0.69,
      "avgVolumeForScore": 848905
    },
    "ma_cross": {
      "ma20": 239.752,
      "ma50": 228.05,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 239.8585,
      "prevMa50": 227.5376,
      "spreadPct": 5.13,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 232.7061,
      "upper": 246.7979,
      "position": "中間"
    },
    "rsi_short": 27.89,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.85
    }
  }
}

Raw metrics JSON

 
{
  "close": 235.5,
  "volume": 724003,
  "changePercent": -0.69
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.